Full metadata record

DC Field Value Language
dc.contributor.authorKim, Seongchan-
dc.contributor.authorLee, Ji-Seon-
dc.contributor.author이효진-
dc.date.accessioned2024-01-12T02:33:47Z-
dc.date.available2024-01-12T02:33:47Z-
dc.date.created2022-09-23-
dc.date.issued2023-01-
dc.identifier.issn1385-8947-
dc.identifier.urihttps://pubs.kist.re.kr/handle/201004/75869-
dc.description.abstractChemical reagents are widely used to block disease development, including tumor progression and increase in abnormal cell populations; however, their consistent usage is limited owing to drug-related side effects and resistance. Although strategies to enhance the intracellular delivery of anticancer drugs, even at low concen-trations, and decrease their undesired side effects have been developed, practical approaches for liver cancer are still limited. Combination therapy has become a solution for improving chemotherapeutic efficacy. Here, we designed a dual-therapeutic platform by engineering graphene oxide (GO) as a multi-functional co-delivery carrier that targets multiple organelles in cells. It delivers two therapeutic reagents as a single vehicle while simultaneously blocking genes in the nucleus and cytoplasm. We adopted a xenograft mouse model of hepatitis C virus infection to verify the therapeutic efficacy of this combinatorial approach. Our strategy successfully sup-pressed tumor growth by enhancing the intracellular accumulation of anticancer drugs even at one-tenth of the conventional dosage of drugs. Simultaneously, the dual-treat method showed a twofold therapeutic efficiency compared with single-drug treatment. By facilitating a combination of individual pharmacological effects, the present functional GO-based delivery system could be a promising multimodal therapeutic platform owing to its high stability, biocompatibility, and multifunctionality.-
dc.languageEnglish-
dc.publisherElsevier BV-
dc.titleCombination treatment of hepatitis C virus-associated hepatocellular carcinoma by simultaneously blocking genes in multiple organelles via functionally engineered graphene oxide-
dc.typeArticle-
dc.identifier.doi10.1016/j.cej.2022.139279-
dc.description.journalClass1-
dc.identifier.bibliographicCitationChemical Engineering Journal, v.452-
dc.citation.titleChemical Engineering Journal-
dc.citation.volume452-
dc.description.isOpenAccessY-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.identifier.wosid000863344600003-
dc.relation.journalWebOfScienceCategoryEngineering, Environmental-
dc.relation.journalWebOfScienceCategoryEngineering, Chemical-
dc.relation.journalResearchAreaEngineering-
dc.type.docTypeArticle-
dc.subject.keywordPlusIN-VITRO-
dc.subject.keywordPlusNANOGRAPHENE OXIDE-
dc.subject.keywordPlusINTRATUMORAL INJECTION-
dc.subject.keywordPlusANTICANCER DRUG-
dc.subject.keywordPlusQUANTUM DOTS-
dc.subject.keywordPlusCANCER-CELLS-
dc.subject.keywordPlusDOXORUBICIN-
dc.subject.keywordPlusNANOPARTICLES-
dc.subject.keywordPlusDELIVERY-
dc.subject.keywordPlusTHERAPY-
dc.subject.keywordAuthorGraphene oxide-
dc.subject.keywordAuthorHepatitis C virus-
dc.subject.keywordAuthorHepatocellular carcinoma-
dc.subject.keywordAuthorCombinatorial drug therapy-
dc.subject.keywordAuthorRNA therapeutics-
Appears in Collections:
KIST Article > 2023
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE